LeonaBio, Inc. filed a Current Report on Form 8-K on November 16, 2026, disclosing the issuance of a press release reporting its financial results for the quarter ended September 30, 2026.

Key Highlights

  • Reporting period: Financial results cover the fiscal quarter ended September 30, 2026.
  • Exchange listing: LeonaBio, Inc. common stock (par value $0.0001 per share) is listed on NASDAQ:LONA.
  • Press release exhibit: The financial results press release, dated November 16, 2026, was furnished as Exhibit 99.1.
  • Signed by: Mark Litton, President and Chief Executive Officer, signed the filing on behalf of the registrant.
  • Investor communications: The company disclosed it uses multiple channels, including social media accounts on X, LinkedIn, Instagram, and Facebook, to communicate material information to investors and the public.

LeonaBio's Q3 2026 Quarterly Results Submission and Disclosure Practices

According to the filing, LeonaBio, Inc., a Delaware-incorporated company headquartered at 18706 North Creek Parkway, Suite 104, Bothell, WA 98011, submitted a Current Report to the Securities and Exchange Commission on November 16, 2026. The report was filed under Item 2.02 (Results of Operations and Financial Condition) and discloses that the company issued a press release on that same date reporting its financial results for the third fiscal quarter ended September 30, 2026. The press release was furnished as Exhibit 99.1 and is attached to the filing.

Under Item 7.01 (Regulation FD Disclosure), the company described how it communicates material information to the public. According to the filing, LeonaBio uses a variety of means, including regulatory filings, press releases, public conference calls, and its investor relations website, as well as social media platforms including its X account (@leonabioinc), LinkedIn account, Instagram account (@leona.bio), and Facebook page. The filing states that "the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information."

The filing notes that the information furnished under Items 2.02 and 7.01, along with the attached exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference. The report was signed by Mark Litton, who serves as President and Chief Executive Officer of LeonaBio, Inc.

What Was Disclosed

LeonaBio, Inc. (NASDAQ:LONA) filed an 8-K on November 16, 2026, furnishing a press release with its financial results for the quarter ended September 30, 2026, and describing its current investor communications channels under Regulation FD.